Skip to main content
Maricer Escalon, MD, Oncology, Miami, FL

Maricer P Escalon MD

Breast Cancer, Hematologic Oncology


Associate Vice President at Lilly

Join to View Full Profile
  • 1611 Nw 12th AveBox 016960 M851Miami, FL 33136

  • Phone+1 305-585-1111

Dr. Escalon is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Imperial College
    Imperial CollegeExecutive MBA, 2014
  • University of Texas Health Science Center at Houston
    University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 2002 - 2005
  • University of Texas Medical School at Houston - Ruiz Dept of Ophthalmology & Visual Science
    University of Texas Medical School at Houston - Ruiz Dept of Ophthalmology & Visual ScienceMSc, Clinical Research, emphasis on Immunology, 2005
  • University of Miami/Jackson Health System
    University of Miami/Jackson Health SystemResidency, Internal Medicine, 1999 - 2002
  • University of Florida College of Medicine
    University of Florida College of MedicineClass of 1999
  • Florida State University
    Florida State UniversityBS, Biochemistry, 1995

Certifications & Licensure

  • AZ State Medical License
    AZ State Medical License 2019 - 2027
  • FL State Medical License
    FL State Medical License 2001 - 2026
  • NC State Medical License
    NC State Medical License 2018 - 2022
  • TX State Medical License
    TX State Medical License 2002 - 2005
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
  • Fellow of the Year Award MD Anderson
  • Young Investigator Award American Society of Clinical Oncology
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Ensysce Biosciences Receives Investigational New Drug Allowance for Its Unique PF614-MPAR™ Opioid with Overdose Protection
    Ensysce Biosciences Receives Investigational New Drug Allowance for Its Unique PF614-MPAR™ Opioid with Overdose ProtectionApril 29th, 2021

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: